It was reported that the molecular mechanism of ribofavin treatment's signifcantly efficacy in MADD patients has been linked to its putative chaperone effects that can offset against inherited folding defects of ETFDH (20). The gene discussed is ETFDH; the disease is multiple acyl-CoA dehydrogenase deficiency.